MARCUS THIEMANN

Allopathic & Osteopathic Physicians|Internal Medicine PALMER, AK NPI 1750876629

General Payments — all program years on this page

$999.10

  • Category: General Payments
  • Program years: PY2019–2023
  • Record count: 44
  • As of (CMS publication): 2026-01-23

Latest program year (PY2023): $439.15 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2023) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $439.1520

By paying entity

Latest program year (PY2023) · sorted by reported total.

By program year

Program yearAmountRecords
2019 $11.681
2020 $19.461
2021 $35.082
2022 $493.7320
2023 $439.1520

Records — PY2023 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1003485519 GlaxoSmithKline, LLC. $14.06 06/13/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1003485729 GlaxoSmithKline, LLC. $13.85 01/11/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1003485733 GlaxoSmithKline, LLC. $22.37 07/19/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1003485737 GlaxoSmithKline, LLC. $22.46 09/26/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1016415133 E.R. Squibb & Sons, L.L.C. $18.72 03/07/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1016415227 E.R. Squibb & Sons, L.L.C. $16.37 07/10/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1016415231 E.R. Squibb & Sons, L.L.C. $16.96 08/15/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1016415239 E.R. Squibb & Sons, L.L.C. $20.28 09/07/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1020010373 Amgen Inc. $28.58 06/27/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1020010375 Amgen Inc. $30.33 09/14/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1026327237 Medtronic, Inc. $13.02 06/29/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1026672819 Exact Sciences Corporation $22.71 12/16/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1048650689 Merck Sharp & Dohme LLC $21.21 10/24/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1048949393 Merck Sharp & Dohme LLC $19.78 08/31/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1050956383 United Therapeutics Corporation $22.62 02/28/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1057229385 Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.18 02/22/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
988761931 Actelion Pharmaceuticals US, Inc. $26.53 07/24/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
988761933 Actelion Pharmaceuticals US, Inc. $33.04 11/01/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
988761935 Actelion Pharmaceuticals US, Inc. $33.48 06/01/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
993289263 Novartis Pharmaceuticals Corporation $27.60 04/06/2023 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.